Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) kicked off on Friday, up 6.47% from the previous trading day, before settling in for the closing price of $8.04. Over the past 52 weeks, BCYC has traded in a range of $6.10-$28.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -0.87% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -30.34%. With a float of $61.47 million, this company’s outstanding shares have now reached $69.20 million.
In an organization with 305 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 78.4%, operating margin of -994.19%, and the pretax margin is -839.74%.
Bicycle Therapeutics Plc ADR (BCYC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Bicycle Therapeutics Plc ADR is 11.18%, while institutional ownership is 57.40%. The most recent insider transaction that took place on Jul 03 ’25, was worth 23,756. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 3,193 shares at a rate of $7.44, taking the stock ownership to the 480,804 shares. Before that another transaction happened on Jul 02 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 2,268 for $7.09, making the entire transaction worth $16,080. This insider now owns 483,997 shares in total.
Bicycle Therapeutics Plc ADR (BCYC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -30.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.85% during the next five years compared to -0.87% drop over the previous five years of trading.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Trading Performance Indicators
Take a look at Bicycle Therapeutics Plc ADR’s (BCYC) current performance indicators. Last quarter, stock had a quick ratio of 14.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.14, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -4.36 in one year’s time.
Technical Analysis of Bicycle Therapeutics Plc ADR (BCYC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.27 million. That was inferior than the volume of 0.33 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.60%.
During the past 100 days, Bicycle Therapeutics Plc ADR’s (BCYC) raw stochastic average was set at 43.23%, which indicates a significant decrease from 85.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.46 in the past 14 days, which was lower than the 0.57 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.99, while its 200-day Moving Average is $13.48. However, in the short run, Bicycle Therapeutics Plc ADR’s stock first resistance to watch stands at $8.97. Second resistance stands at $9.38. The third major resistance level sits at $9.91. If the price goes on to break the first support level at $8.03, it is likely to go to the next support level at $7.50. Assuming the price breaks the second support level, the third support level stands at $7.09.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Key Stats
The company with the Market Capitalisation of 592.35 million has total of 69,254K Shares Outstanding. Its annual sales at the moment are 35,280 K in contrast with the sum of -169,030 K annual income. Company’s last quarter sales were recorded 9,980 K and last quarter income was -60,750 K.
